20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
24 citations
,
November 2015 in “Frontiers in Genetics” Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
November 2025 in “Bioactive Materials” TQC shows promise for better hair regrowth in treating hair loss.
14 citations
,
January 2010 in “Dermatology” Some people with congenital triangular alopecia have a central tuft of hair in the bald patch, but the cause is unknown.
1 citations
,
September 2024 in “Indian Journal of Postgraduate Dermatology” Trichoscopy effectively diagnoses temporal triangular alopecia in children.
May 2024 in “News Digital Object Group” 193 citations
,
June 2007 in “The Plant Journal” GhDET2 is crucial for cotton fiber growth.
1 citations
,
December 1989 in “PubMed” Tretinoin's effectiveness for hair loss is unclear and needs more research.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
42 citations
,
June 2019 in “Aging” 3,4,5-tri-O-caffeoylquinic acid promotes hair growth by activating the β-catenin pathway.
7 citations
,
January 2022 in “Molecules” Tectoridin helps human hair cells grow and makes mouse hair longer, suggesting it could treat hair loss.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
March 2021 in “Research Square (Research Square)” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
April 2018 in “Journal of Investigative Dermatology” Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
Introducing the OTC gene improved symptoms in mice with OTC deficiency.
12 citations
,
May 2015 in “Molecular Medicine Reports” Troxerutin helps protect skin cells from oxidative stress and may be good for treating hair loss.
July 2026 in “Journal of the American Academy of Dermatology”
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
August 2002 in “Inpharma Weekly”
June 2026 in “Journal of General-Procedural Dermatology & Venereology Indonesia” Tofacitinib effectively improves lichen planus pigmentosus symptoms.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.
286 citations
,
April 2009 in “The journal of neuroscience/The Journal of neuroscience” TRPA1 is crucial for mechanical sensitivity in skin sensory neurons.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
26 citations
,
July 2014 in “Analytical Chemistry Research” Method can accurately measure five BPH drugs at once.